- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04360889
Lipid Peroxidation and Options Antioxidant Therapy for Secondary Lymphedema of the Lower Extremities
August 3, 2022 updated by: Ryazan State Medical University
A single-center, open, prospective, randomized, controlled clinical trial will include 120 patients with lower limb lymphedema who undergo treatment in an office-based vascular lab at the Ryazan regional clinical cardiology dispensary, Ryazan, Russia.
The patients will be recruited by the staff of the Department of cardiovascular, endovascular, operative surgery, and topographic anatomy, Ryazan state I.P. Pavlov medical university, Russia.
The study will include patients who meet the inclusion criteria and do not meet the exclusion criteria.
Patients will be divided into 4 groups, 30 subjects each.
Group 1-patients with lower limb lymphedema who will receive conservative therapy with elastic compression and an antioxidant (Tocopherol-400 IU/day); Group 2-patients with lower limb lymphedema who will receive conservative therapy with Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)-1000mg/day) in addition to elastic compression; Group 3-patients with lower limb lymphedema who will be treated with elastic compression; Group 4- healthy volunteers with no history or clinical signs of venous or lymphatic disease; The duration of this study for each subject will be a maximum of 90 days.
Pre-screening and screening will involve 200 subjects with a total of 120 subjects who will be randomized into the study.
Peripheral blood samples will be collected to evaluate the activity of biochemical markers of endothelial function; the quality of life will also be assessed.
Study Overview
Status
Completed
Conditions
Detailed Description
Research methods:
- Physical examination;
- peripheral blood sampling (assessment of the concentration of the markers of endothelial dysfunction, including malondialdehyde (MDA), superoxide dismutase (SD), catalase( CAT), glutathione peroxidase (GP). MDA concentration will be determined with a competitive enzyme immunoassay (ELISA), which will be performed using a General MDA assessment kit (manufacturer: USCN Life Science Inc. US-CEA597GE). CAT concentration will be determined using a competitive enzyme immunoassay (ELISA), which will be performed with a kit for quantitative in vitro assessment of catalase (manufacturer: USCN Life Science Inc. US-SEC418Hu). GP concentration will be determined with a competitive enzyme immunoassay (ELISA), which will be performed using a glutathione peroxidase quantification set (abfrontier supplier, Republic of Korea - LF- EK0110). SOD concentration will be determined using a competitive enzyme immunoassay (ELISA), which will be performed using a total superoxide dismutase detection kit (supplier Cayman Chemical Company, US - 706002).
- Lower limb venous sonography with a linear 5-13 MHz probe;
- Patient questionnaire using a Russian-language version of the Quality of life questionnaire "SF-36 Health Status Survey"
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ryazan', Russian Federation, 390026
- Ryazan State Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Secondary lymphedema of the lower extremities
- Signed Informed Consent Form
Exclusion Criteria:
- varicose veins of the lower extremities,
- deep vein thrombosis,
- post-thrombotic disease,
- obliterating
- atherosclerosis of the lower limb arteries,
- pregnancy,
- lactation,
- cancer,
- acute violation of cerebral circulation in the anamnesis,
- trophic lesions of the skin of the lower extremities,
- diabetes mellitus
- an infectious disease with a history of three months prior to inclusion in the study,
- heart failure,
- kidney failure,
- pulmonary insufficiency.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tocopherol
patients with lower limb lymphedema who will receive conservative therapy with elastic compression and an antioxidant (Tocopherol-400 IU/day) - 90 days
|
patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
|
Experimental: Micronised purified flavonoid fraction
patients with lower limb lymphedema who will receive conservative therapy with Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)-1000mg/day) in addition to elastic compression - 90 days
|
Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day
|
Other: Elastic compression
patients with lower limb lymphedema who will be treated with elastic compression - 90 days
|
patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
|
No Intervention: Healthy volunteers
healthy volunteers with no history or clinical signs of venous or lymphatic disease - 90 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The malleolar volume of the limb
Time Frame: 90 days
|
The circumference at the level of the narrowest part of the lower leg, measured in centimeters
|
90 days
|
The Level Of Catalase
Time Frame: 90 days
|
Biochemical indicator of the functional state of the endothelium.
Catalase concentration will be determined using a competitive enzyme immunoassay (ELISA), which will be performed with a kit for quantitative in vitro assessment of catalase (manufacturer: USCN Life Science Inc. US-SEC418Hu).
Unit of measurement ng / ml
|
90 days
|
The Level Of Superoxide Dismutase
Time Frame: 90 days
|
Biochemical indicator of the functional state of the endothelium.
Superoxide Dismutase concentration will be determined using a competitive enzyme immunoassay (ELISA), which will be performed using a total superoxide dismutase detection kit (supplier Cayman Chemical Company, US - 706002).
Unit of measurement UI / ml
|
90 days
|
The Level Of Glutathione Peroxidase
Time Frame: 90 days
|
Biochemical indicator of the functional state of the endothelium.
Glutathione Peroxidase concentration will be determined with a competitive enzyme immunoassay (ELISA), which will be performed using a glutathione peroxidase quantification set (abfrontier supplier, Republic of Korea - LF- EK0110).
Unit of measurement ng / ml
|
90 days
|
The level of Malondialdehyde
Time Frame: 90 days
|
Biochemical indicator of the functional state of the endothelium.
Malondialdehyde concentration will be determined with a competitive enzyme immunoassay (ELISA), which will be performed using a General MDA assessment kit (manufacturer: USCN Life Science Inc. US-CEA597GE).
Unit of measurement ng / ml
|
90 days
|
Quality of life indicators: questionnaire
Time Frame: 90 days
|
Patient questionnaire using a Russian-language version of the Quality of life questionnaire "Short Form-36 Health Status Survey".
8 indicators.
Indicator from 0 to 100.
Higher scores mean a better outcome.
|
90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2019
Primary Completion (Actual)
August 3, 2022
Study Completion (Actual)
August 3, 2022
Study Registration Dates
First Submitted
April 18, 2020
First Submitted That Met QC Criteria
April 23, 2020
First Posted (Actual)
April 24, 2020
Study Record Updates
Last Update Posted (Actual)
August 4, 2022
Last Update Submitted That Met QC Criteria
August 3, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDA-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lower Extremity Lymphedema
-
The First Hospital of Jilin UniversityRecruitingLower Extremity LymphedemaChina
-
Istanbul UniversityCompletedLower Extremity LymphedemaTurkey
-
University of OttawaMcGill University; Horizon Health Network; University of New Brunswick; New Brunswick...UnknownLymphedema of Upper Limb | Mastectomy Related Lymphedema | Lymphedema of Lower Extremity
-
Koç UniversityNot yet recruitingLower Extremity Lymphedema
-
Tactile MedicalCompletedLower Extremity Lymphoedema | Leg LymphoedemaUnited Kingdom
-
Istanbul Medeniyet UniversityNot yet recruitingLower Extremity LymphedemaTurkey
-
Koya Medical, Inc.CompletedLymphedema | Secondary Lymphedema | Chronic Venous Insufficiency | Lymphedema Lower ExtremityUnited States
-
University of Texas at AustinCompletedUpper Extremity Dysfunction | Lower Extremity ProblemUnited States
-
3MWithdrawnLower Extremity Diabetic Leg Wounds | Lower Extremity Venous Leg Wounds | Lower Extremity Mixed Aetiology Leg WoundsUnited Kingdom
-
StendoCompletedPrimary Lower Limb Lymphedema | Secondary Lower Limb LymphedemaFrance
Clinical Trials on Tocopherol
-
University of North Carolina, Chapel HillCompletedAllergic Rhinitis | Mild AsthmaUnited States
-
University of North Carolina, Chapel HillNational Center for Complementary and Integrative Health (NCCIH)Completed
-
New Mexico Cancer Care AllianceTerminatedProstate CancerUnited States
-
University of North Carolina, Chapel HillNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Hospices Civils de LyonCompleted
-
University of North Carolina, Chapel HillNational Institute of Environmental Health Sciences (NIEHS)CompletedGamma Tocopherol Serum LevelsUnited States
-
University of North Carolina, Chapel HillNational Center for Complementary and Integrative Health (NCCIH)CompletedAsthma | Allergy | Asthmatic | AllergicUnited States
-
University of North Carolina, Chapel HillNational Institute of Environmental Health Sciences (NIEHS)CompletedAllergic AsthmaUnited States
-
Hadassah Medical OrganizationWithdrawn
-
University of North Carolina, Chapel HillNational Institute of Environmental Health Sciences (NIEHS)CompletedAsthma | Airway InflammationUnited States